A field trial of recombinant Schistosoma japonicum paramyosin as a potential vaccine in naturally-infected water buffaloes

The overall aims of this project are to assess the safety and immunogenicity of the Schistosoma japonicum vaccine paramyosin among water buffaloes residing in endemic areas. The study was conducted in four villages in Leyte, the Philippines, an area highly endemic for schistosomiasis japonica. One hundred and fifteen (N=115) animals provided baseline stool samples for coprologic examination, with preliminary results using FLOTAC showing a 10% prevalence of schistosomiasis. Forty-nine (N=49) animals consented to treatment with 25 mg/kg Praziquantel, and 40, 36 and 32 animals consented to the first, second and third dose of the paramyosin vaccine, respectively. The safety trial involved the first 20 animals and included skin testing, vaccination, anaphylaxis monitoring, as well as hematology and serum chemistry analysis. Skin tests revealed that only three out of 20 animals exhibited redness at the injection site, with none greater than 1 cm. None of the animals exhibited anaphylaxis, and all hematology and serum chemistry markers were within normal range or were similar to pre-vaccination levels. None of the 40 animals administered with the first dose exhibited anaphylaxis, nor any of the subsequent vaccine doses. Immunogenicity assessment of sera collected prior to every vaccination and one month after the last dose showed that the paramyosin vaccine induced robust antibody responses to all animals, as assessed by ELISA. The cytokine levels of whole blood culture supernatants will be further assessed. Our findings demonstrate that the S. japonicum paramyosin vaccine is a safe, well-tolerated and immunogenic treatment among water buffalos residing in endemic areas.